GLP-2 T the science.

Tirzepatide is a single synthetic peptide engineered to activate two incretin receptors at once — the GIP receptor and the GLP-1 receptor. Like other long-acting incretin peptides, it carries a fatty-acid modification that supports albumin binding and a once-weekly dosing profile in the studied formulations.

As a prescription medicine, tirzepatide is FDA-approved and in clinical use for type 2 diabetes and for chronic weight management. The compound discussed on this page is supplied strictly as a research material and is not the approved pharmaceutical product.

Tirzepatide’s research interest comes from engaging two incretin pathways together:

• GLP-1 receptor — associated with glucose-dependent insulin secretion and satiety signaling.
• GIP receptor — a second incretin pathway studied alongside GLP-1 for its insulinotropic and metabolic effects.
• Combined signaling — research examines how dual activation differs from single-receptor GLP-1 agonism.

Tirzepatide has an extensive human clinical evidence base:

• Obesity trials (SURMOUNT program). A randomized, placebo-controlled trial published in the New England Journal of Medicine reported substantial body-weight reduction over 72 weeks in adults with obesity.
• Diabetes research (SURPASS program). Tirzepatide has been evaluated across large randomized trials in type 2 diabetes, including glycemic and body-weight endpoints.

These findings come from trials of the medicine under medical supervision. They are reported here as research context and do not represent claims about the research material supplied on this page.

Tirzepatide is supported by extensive human clinical-trial data and is approved as a prescription medicine. That approval applies to the pharmaceutical product under medical supervision — not to research material. The compound supplied here is for research use only, not for human or veterinary use, and no dosing or therapeutic claim is made about it.